Questions? Feedback? powered by Olark live chat software
All Site

Betting Twelve Billion Dollars on Cellular Immunotherapy

In the latest vote of confidence that cellular immunotherapy is going to live up to its potential for transforming the way cancer is treated, this week Gilead Sciences purchased Kite Pharma, a leader in the development of chimeric antigen receptor (CAR) T cells, for $11.9 billion dollars.


See the new Minifors 2 at PEWS.

Join us at the Protein Expression Workshop meeting for a hands-on demonstration of the new Minifors 2 from Infors-HT and the new eve bioprocess control software.


Parasitic Worm Spit Speeds up Wound Recovery

Findings from the new study—published recently in the Journal of Medicinal Chemistry in an article entitled “Development of a Potent Wound Healing Agent Based on the Liver Fluke Granulin Structural...

Total: 49 posts